PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Patricio Schlottmann, MD, discusses dual inhibition of the Ang-2 and VEGF pathways.
Schlottman, of the Organización Médica de Investigación in Buenos Aires, Argentina, said dual inhibition with agents such as faricimab has the potential to provide clinical benefits such as reduced leakage, inflammation and fibrosis regardless of the anti-VEGF dose.
“When you treat a patient aiming for a dual blockage with taking care of the angiopoietin pathway and also blocking the VEGF